Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Oct 3, 2012

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Sizing the Market for Contract Manufacturing

Measuring the size of the market for contract manufacturing services requires a careful hand.
Oct 2, 2012

Measuring the size of the market for contract manufacturing services requires a careful hand.

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Sep 2, 2012

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Sep 1, 2012

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

CROs and CMOs Have Cause to Celebrate

Annual survey shows strong growth for service providers and promises to continue into 2013. This article is part of a special issue on outsourcing.
Aug 1, 2012

Annual survey shows strong growth for service providers and promises to continue into 2013.

Channeling Steve Jobs

Service providers must focus on delivering a superior customer experience.
May 2, 2012

Service providers must focus on delivering a superior customer experience.

Channeling Steve Jobs

Service providers must focus on delivering a superior customer experience.
May 1, 2012

Service providers must focus on delivering a superior customer experience.

CMOs Face a Kodak Moment

The evolving bio/pharmaceutical business model poses risk for CMOs.
Apr 4, 2012

The evolving bio/pharmaceutical business model poses risk for CMOs.

CMOs Face a Kodak Moment

The evolving bio/pharmaceutical business model poses risk for CMOs.
Mar 2, 2012

The evolving bio/pharmaceutical business model poses risk for CMOs.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here